Ribociclib is an oral Cyclin-Dependent Kinase 4 and 6 (CDK 4/6) inhibitor, approved by the Food and Drug Administration for the treatment of HR+/HER2- advanced breast cancer. The Essential Medicines List expert committee recognised its potential for future inclusion and recommended to MPP to explore licensing opportunities.